Confo Therapeutics

Lilly Initiates Phase 2 Trial for Novel Non-Opioid Pain Therapy CFTX-1554

- Eli Lilly has dosed the first patients in a Phase 2a clinical trial evaluating CFTX-1554, a novel angiotensin II type 2 receptor antagonist for chronic pain treatment. - The compound represents a non-opioid approach to pain management that aims to avoid centrally mediated side effects such as addiction and sedation. - CFTX-1554 was discovered by Confo Therapeutics using their proprietary GPCR-targeting platform and is being developed under a licensing agreement worth up to $590 million in potential milestone payments. - This marks the first candidate from Confo's proprietary technology platform to advance into Phase 2 clinical development.